LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade

Yi Liu; Brian Debo; Mingfeng Li; Zhennan Shi; Wanqiang Sheng; Yang Shi

doi:10.1038/s41467-021-27179-7

Nature Communications (Nov 2021)

LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade

Yi Liu,
Brian Debo,
Mingfeng Li,
Zhennan Shi,
Wanqiang Sheng,
Yang Shi

Affiliations

Yi Liu: Division of Newborn Medicine and Epigenetics Program, Boston Children’s Hospital, Harvard Medical School
Brian Debo: Division of Newborn Medicine and Epigenetics Program, Boston Children’s Hospital, Harvard Medical School
Mingfeng Li: Department of Neuroscience and Kavli Institute for Neuroscience, Yale School of Medicine
Zhennan Shi: Division of Newborn Medicine and Epigenetics Program, Boston Children’s Hospital, Harvard Medical School
Wanqiang Sheng: Division of Newborn Medicine and Epigenetics Program, Boston Children’s Hospital, Harvard Medical School
Yang Shi: Division of Newborn Medicine and Epigenetics Program, Boston Children’s Hospital, Harvard Medical School

DOI: https://doi.org/10.1038/s41467-021-27179-7
Journal volume & issue: Vol. 12, no. 1
pp. 1 – 16

Abstract

Read online

Dynamic changes in chromatin landscape affect CD8+ T cell phenotype and function in chronic infections and cancer. Here the authors show that targeting the histone demethylase LSD1 increases the persistence of progenitor exhausted CD8+ T cells, improving response to immune checkpoint blockade in preclinical cancer models.

Published in Nature Communications

ISSN: 2041-1723 (Online)
Publisher: Nature Portfolio
Country of publisher: United Kingdom
LCC subjects: Science
Website: https://www.nature.com/ncomms/

About the journal